Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacitidine and Sargramostim Maintenance in AML/MDS
NCT01700673Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2013
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, sargramostim in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jun 2013; status: completed.
02
Drugs
azacitidinesargramostim
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01700673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01700673.